Copyright
©The Author(s) 2024.
World J Gastrointest Surg. Jan 27, 2024; 16(1): 196-204
Published online Jan 27, 2024. doi: 10.4240/wjgs.v16.i1.196
Published online Jan 27, 2024. doi: 10.4240/wjgs.v16.i1.196
Table 1 Patients’ baseline characteristics
Variable | PVB group (n = 28) | Control group (n = 30) | P value |
Age (yr) | 56.4 ± 9.2 | 58.3 ± 8.7 | 0.42 |
Sex (male/female) | 16/12 | 18/12 | 0.72 |
Body mass index (kg/m2) | 23.5 ± 3.1 | 24.2 ± 2.9 | 0.34 |
ASA physical status (I/II/III) | 6/16/6 | 8/14/8 | 0.81 |
Tumor size (cm) | 4.6 ± 1.2 | 4.8 ± 1.3 | 0.56 |
Tumor number (single/multiple) | 12/16 | 14/16 | 0.77 |
Procedure duration (min) | 82.5 ± 15.4 | 85.3 ± 16.2 | 0.51 |
Table 2 Visual analog scale score for pain at different time points after the procedure
Time point | PVB group (n = 28) | Control group (n = 30) | P value |
6 h after the procedure | 2.1 ± 1.2 | 4.3 ± 1.4 | < 0.001 |
12 h after the procedure | 1.8 ± 1.0 | 3.7 ± 1.3 | < 0.001 |
24 h after the procedure | 1.4 ± 0.9 | 3.2 ± 1.2 | < 0.001 |
48 h after the procedure | 1.1 ± 0.8 | 2.8 ± 1.1 | < 0.001 |
Table 3 Consumption of sufentanil during and after the procedure
Variable | PVB group (n = 28) | Control group (n = 30) | P value |
Sufentanil consumption during the procedure (μg) | 15.7 ± 4.2 | 25.3 ± 5.6 | < 0.001 |
Sufentanil consumption after the procedure (μg) | 32.1 ± 8.7 | 48.6 ± 10.4 | < 0.001 |
Total sufentanil consumption (μg) | 47.8 ± 11.3 | 73.9 ± 13.2 | < 0.001 |
Table 4 Incidence of adverse events during and after the procedure
Variable | PVB group (n = 28) | Control group (n = 30) | P value |
Nausea (%) | 7.1 | 26.7 | 0.03 |
Vomiting (%) | 3.6 | 16.7 | 0.04 |
Respiratory depression (%) | 0 | 10 | 0.02 |
Hypotension (%) | 3.6 | 6.7 | 0.65 |
Bradycardia (%) | 0 | 3.3 | > 0.99 |
Puncture site hematoma (%) | 0 | 0 | > 0.99 |
Table 5 Levels of inflammatory markers before and after the procedure
Variable | Time point | PVB group (n = 28) | Control group (n = 30) | P value |
WBC (× 109/L) | Before the procedure | 6.8 ± 1.5 | 7.1 ± 1.6 | 0.36 |
24 h after the procedure | 9.4 ± 2.1 | 12.3 ± 2.7 | < 0.001 | |
48 h after the procedure | 8.2 ± 1.8 | 10.5 ± 2.4 | < 0.001 | |
NEUT% (%) | Before the procedure | 65.3 ± 8.5 | 66.7 ± 9.2 | 0.54 |
24 h after the procedure | 72.4 ± 7.6 | 80.5 ± 6.8 | < 0.001 | |
48 h after the procedure | 69.2 ± 7.2 | 76.3 ± 7.4 | < 0.001 | |
CRP (mg/L) | Before the procedure | 5.2 ± 1.4 | 5.6 ± 1.6 | 0.32 |
24 h after the procedure | 18.7 ± 4.3 | 26.4 ± 5.9 | < 0.001 | |
48 h after the procedure | 14.3 ± 3.8 | 20.6 ± 5.2 | < 0.001 | |
PCT (ng/mL) | Before the procedure | 0.12 ± 0.04 | 0.13 ± 0.05 | 0.46 |
24 h after the procedure | 0.28 ± 0.08 | 0.42 ± 0.11 | < 0.001 | |
48 h after the procedure | 0.22 ± 0.07 | 0.34 ± 0.09 | < 0.001 |
- Citation: Xiong YF, Wei BZ, Wang YF, Li XF, Liu C. Paravertebral block's effect on analgesia and inflammation in advanced gastric cancer patients undergoing transarterial chemoembolization and microwave ablation. World J Gastrointest Surg 2024; 16(1): 196-204
- URL: https://www.wjgnet.com/1948-9366/full/v16/i1/196.htm
- DOI: https://dx.doi.org/10.4240/wjgs.v16.i1.196